

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.  
33421-US-PCT  
APPLICATION NO.  
10/574,745  
APPLICANT  
SHETTY ET AL.  
FILING DATE

Group

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA	2003/162759	8/28/03	Rocha et al.			
	AB	2002/156057	10/24/02	Bubien			
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AM	0 831 910 B	11/21/01	Europe			<input type="checkbox"/>	<input type="checkbox"/>
	AN						<input type="checkbox"/>	<input type="checkbox"/>
	AO						<input type="checkbox"/>	<input type="checkbox"/>
	AP						<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AR	Pitt et al., "The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure," New England Journal of Medicine, The Massachusetts Medical Society, Vol. 341, No. 10, pp. 709-717 (1999)
	AS	Sawathiparnich et al., "Effect of combined AT1 receptor and aldosterone receptor antagonism on plasminogen activator inhibitor-1," Journal of Clinical Endocrinology and Metabolism, Vol. 88, No. 8, pp. 3867-3873 (2003)
	AT	Pitt et al., "Effects of Eplerenone, Enalapril, and Eplerenone/Enalapril in Patients with Essential Hypertension and Left Ventricular Hypertrophy. The 4E-Left Ventricular Hypertrophy Study, Circulation, pp. 1831-1838 (2003)

EXAMINER

/Samira Jean-louis/

DATE CONSIDERED

11/21/2009

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.J.L.